As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
17h
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High
Reviva Pharmaceuticals' brilaroxazine shows promise for schizophrenia, but regulatory and financial risks persist. Read why ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has initiated a Phase 3 study titled ‘A ...
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...
CINCINNATI, Ohio. (Ivanhoe Newswire) --- Schizophrenia - the statistics are terrifying; more than 3.7 million people are living with it right now in the United States. If left untreated it can be ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...
Verywell Health on MSN
What is undifferentiated schizophrenia?
An outdated, catch-all diagnosis when symptoms are difficult to classify ...
A major scientific review reveals a deep knowledge gap in how cognition is affected when schizophrenia and personality disorders occur together.
People living with schizophrenia continue to battle not just their symptoms, delayed diagnoses and access to quality healthcare, but also the societal demons of misinformation, stigma and deep-rooted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback